

Targeted Immunotherapy for Multiple Myeloma: Novel Mutant CCL27 Binders Targeting CCR10

Tech ID: 34320 / UC Case 2025-048-0

TECHNOLOGY DESCRIPTION

Addressing the critical unmet need of resistance and relapse associated with current therapies, this innovative approach offers a powerful alternative to BCMA-targeted treatments. Our engineered CCL27 mutants exhibit significantly enhanced binding affinity to CCR10, enabling precise and effective targeting of cancer cells.

Versatile in application, these binders can be utilized across a range of therapeutic platforms, including CAR T-cells and bispecific antibodies. Preclinical data demonstrates that mutant CCL27 CAR T cells exhibit superior cytotoxicity against multiple myeloma cell lines in vitro and significantly improved efficacy in vivo, outperforming BCMA-targeted therapies. This next-generation solution redefines possibilities for patients battling relapsed or resistant multiple myeloma.

STAGE OF DEVELOPMENT

Pre-clinical proof of concept.

RELATED MATERIALS

- ▶ [In vivo genome-wide CRISPR screens in human T cells to enhance T cell therapy for solid tumors](#) - 09/24/2025

PATENT STATUS

Patent Pending

CONTACT

Gemma E. Rooney
Gemma.Rooney@ucsf.edu
 tel: 415-625-9093.



OTHER INFORMATION

KEYWORDS

Multiple Myeloma, CART, CCR10, CCL27, Binders, BCMA

CATEGORIZED AS

- ▶ **Medical**
 - ▶ Disease: Cancer
 - ▶ Therapeutics

RELATED CASES

2025-048-0

ADDRESS

UCSF

Innovation Ventures

600 16th St, Genentech Hall, S-272,
 San Francisco, CA 94158

CONTACT

Tel:

innovation@ucsf.edu

<https://innovation.ucsf.edu>

Fax:

CONNECT

 Follow  Connect

© 2025, The Regents of the University of California

[Terms of use](#) [Privacy Notice](#)